Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 - Nutraceuticals World

What are you searching for?

Sign in
Research

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Indication: Macular degeneration

Source: 2004 American Academy of Ophthalmology and European Society of Ophthalmology Joint Meeting, New Orleans, LA

Research: Investigators studied the effect of Phototrop® on 106 patients in the early stages of age-related macular degeneration (AMD). The objective of the double-blind, placebo-controlled, single-center study carried out in Hungary was to determine how Phototrop influenced visual functions of patients ages 55 to 70 years with early AMD after 12 months of treatment compared to the placebo group. The study was also aimed at evaluating changes in fundus alterations or the drusen-covered areas. Finally, the safety of the product was considered.

Results: The researches found that the patients experienced a statistically significant decrease in drusen (yellow deposits that accumulate under the retina). They concluded that the findings justify an assumption that an appropriate combination of mitotropic compounds (those that influence mitochondrial metabolism) improves visual functions in early AMD and diminishes the risk of vision loss associated with more advanced stages of the disease.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters